| Therapeutic | Cadonilimab |
| Target 1 | PDCD1 |
| Heavy Chain 1 | QVQLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA |
| Light Chain 1 | DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK |
| 100% seqID Fv 1 Structure | None |
| 99% seqID Fv 1 Structure | None |
| 95-98% seqID Fv 1 Structure | None |
| Target 2 | CTLA4 |
| Heavy Chain 2 | QVVLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA |
| Light Chain 2 | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNFPNWVQQKPGQAPRSLIGGTNNKASWTPARFSGSLLGGKAALTISGAQPEDEAEYYCALWYSNHWVFGCGTKLTVL |
| 100% seqID Fv 2 Structure | None |
| 99% seqID Fv 2 Structure | None |
| 95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
| Format | Bispecific Mixed mAb and scFv |
| Isotype | G1;na |
| Highest Clinical Trial (Aug '23) | Approved |
| Estimated Status (Aug '23) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2020 |
| INN Year Recommended | 2021 |
| Companies Involved | Akeso Biopharma |
| Conditions Approved | Cervical cancer |
| Conditions Active | Non-small cell lung cancer, Solid tumours, Peripheral T/NK cell lymphoma, Hepatocellular carcinoma, Gastic adenocarcinoma, Nasopharyngeal carcinoma |
| Conditions Discontinued | na |
| Notes | (June '22: Corrected FWH1 and FWL2 sequences) |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
